Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z9MR
|
|||
| Former ID |
DIB013165
|
|||
| Drug Name |
TG-1042
|
|||
| Synonyms |
TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene
Click to Show/Hide
|
|||
| Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Discontinued in Phase 2 | [1] | |
| Company |
Transgene SA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010265) | |||
| REF 2 | Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.